Cardiovascular drugs and therapy · 2025
The Combined Empagliflozin and Sacubitril/Valsartan Therapy Attenuates Isoproterenol-Induced Heart Failure in Rats: Functional, Molecular, and Structural Insights.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Muric Maja, Srejovic Ivan, Novakovic Jovana, Zivkovic Vladimir, Jovic Jovana Joksimovic, Sretenovic Jasmina, Nikolic Marina, Lazarevic Nevena, Andjic Marijana, Kocovic Aleksandar, Uzelac Jovana Jakovljevic, Bolevich Sergey, Jakovljevic Vladimir
Аннотация
PURPOSE: The idea behind this study was to assess the effects of empagliflozin and sacubitril/valsartan and their combination on isoproterenol-induced heart failure (HF) and underlying molecular mechanisms.
METHODS: HF was induced with 7-day isoproterenol (5 mg/kg daily), confirmed by ejection fraction below 55% after 4 weeks. HF rats received empagliflozin, sacubitril/valsartan, or both for 4 weeks. Parameters measured included hemodynamics, cardiac function, redox status, and histomorphology.
RESULTS: Isoproterenol impaired hemodynamics and cardiac function, increased oxidative damage, and altered cardiac structure. All treatments were cardioprotective; however, combined empagliflozin and sacubitril/valsartan therapy had the most pronounced effect.
CONCLUSION: Combined empagliflozin and sacubitril/valsartan showed superior cardioprotection in HF, primarily by enhancing antioxidative effects. These findings support early use of both drugs in HF treatment.
METHODS: HF was induced with 7-day isoproterenol (5 mg/kg daily), confirmed by ejection fraction below 55% after 4 weeks. HF rats received empagliflozin, sacubitril/valsartan, or both for 4 weeks. Parameters measured included hemodynamics, cardiac function, redox status, and histomorphology.
RESULTS: Isoproterenol impaired hemodynamics and cardiac function, increased oxidative damage, and altered cardiac structure. All treatments were cardioprotective; however, combined empagliflozin and sacubitril/valsartan therapy had the most pronounced effect.
CONCLUSION: Combined empagliflozin and sacubitril/valsartan showed superior cardioprotection in HF, primarily by enhancing antioxidative effects. These findings support early use of both drugs in HF treatment.
Предметные рубрики MeSH
AnimalsBenzhydryl CompoundsHeart FailureBiphenyl CompoundsAminobutyratesValsartanDrug CombinationsMaleGlucosidesIsoproterenolDisease Models, AnimalSodium-Glucose Transporter 2 InhibitorsVentricular Function, LeftOxidative StressTetrazolesRatsAntioxidantsHemodynamicsStroke VolumeRats, Sprague-DawleyVentricular RemodelingAngiotensin Receptor Antagonists